All treatments
Treatment
000 mg powder and solvent for solution for infusion. clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Double-blind, Randomized, Active-control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and safety of SAR447537 (INBRX-101) Compared to Plasma Derived Apha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Adults with Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
This study compares a new medicine, INBRX-101, with standard treatment for Alpha-1 Antitrypsin Deficiency (AATD) emphysema. It looks at how the medicines work in the body, their effects, and if they are safe, to help people with this lung condition.
For: Alpha-1 Antitrypsin Deficiency (AATD) EmphysemaDenmark · Sweden · Ireland - Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase 2/3, Multicenter, randOmized, Double-blind, placebo-controlled, stUdy to evaLuate the safety and efficacy of Alpha-1 AntiTrypsin for the prEvention of graft versus-host disease in patients receiving hematopoietic cell transplant (MODULAATE Study)
This study looks at a medicine called Alpha-1 AntiTrypsin (Respreeza) to see if it can prevent a serious problem called graft-versus-host disease (GVHD) in people having a stem cell transplant. It will check if the medicine is safe and if it works.
For: Acute Graft versus host diseaseSpain · Italy · Germany